Expression of DLL3 in small cell lung cancer and its application in targeted therapy / 国际肿瘤学杂志
Journal of International Oncology
; (12): 366-369, 2019.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-751723
Biblioteca responsável:
WPRO
ABSTRACT
Small cell lung cancer (SCLC) has a poor biological behavior,high probability of recurrence and metastasis,and limited treatment.The Notch signaling pathway is an evolutionarily conserved pathway that regulates the growth of many cell types through local cell-cell interactions.It controls the differentiation,proliferation and survival of cells.As a ligand for the Notch pathway,delta-like protein 3 (DLL3) is highly expressed on the membrane of SCLC cells.DLL3 plays an important role in cancer initiation and epithelial mesenchymal transition,invasion and metastasis of SCLC.Rovalpituzumab tesirine is a conjugate of directed against DLL3,which shows great potential for SCLC therapy.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of International Oncology
Ano de publicação:
2019
Tipo de documento:
Artigo